Premium
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
Author(s) -
Lontok Erik,
Harrington Patrick,
Howe Anita,
Kieffer Tara,
Lennerstrand Johan,
Lenz Oliver,
McPhee Fiona,
Mo Hongmei,
Parkin Neil,
PilotMatias Tami,
Miller Veronica
Publication year - 2015
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.27934
Subject(s) - medicine , hepatitis c virus , clinical trial , drug resistance , drug , hepatitis c , virology , hepacivirus , virus , intensive care medicine , immunology , pharmacology , biology , microbiology and biotechnology
Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct‐acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials. Conclusion : This report provides a comprehensive, systematic review of all resistance information available from sponsors’ trials as a tool to inform the HCV drug development field. (H epatology 2015;62:1623–1632)